Browse EX-10 agreements

TRANSITION AND RELEASE AGREEMENT

This Transition and Release Agreement (the “Agreement”) is made and entered into by and among John Mitchell (“Employee”), PACS Group, Inc. (“PubCo”) and Providence Administrative Consulting Services, Inc. (together with PubCo, the “Company”). This Agreement shall be effective on the date on which Employee executes this Agreement (the “Effective Date”). The purpose of this Agreement is to provide separation pay to ease Employee’s transition from the Company in connection with Employee’s retirement, to provide for the transition of Executive’s role with the Company from that of Chief Legal Officer to that of a non-employee consultant to the Company, effective as of the Separation Date (as defined below), and to settle and resolve any and all disputes and controversies of any nature existing between Employee and the Company, including, but not limited to, any claims arising out of Employee’s employment with, and separation from, the Company.

1.Separation of Employment.

…

THIS CONVERTIBLE PROMISSORY NOTE (“NOTE”) AND THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), APPLICABLE STATE LAW, OR APPLICABLE LAWS OF ANY FOREIGN JURISDICTION, AND MAY NOT BE SOLD, OFFERED FOR SALE, DISTRIBUTED, ASSIGNED, OFFERED, PLEDGED OR OTHERWISE TRANSFERRED UNLESS (A) THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND APPLICABLE STATE OR FOREIGN SECURITIES LAWS COVERING ANY SUCH TRANSACTION OR (B) SUCH TRANSACTION IS EXEMPT FROM REGISTRATION UNDER THE SECURITIES ACT AND APPLICABLE STATE OR FOREIGN SECURITIES LAWS COVERING SUCH TRANSACTION.

CONVERTIBLE PROMISSORY NOTE

Principal Amount: $500,000.00	September 15,2026

…

** **

COMMON STOCK PURCHASE WARRANT DSS, INC.

** **

Warrant Shares: 8,000,000

Issue Date: September 15, 2026

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Alset Inc. or their assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00PM (New York City time) on the fifth anniversary of the Issue Date (the “Termination Date”) (or if any portion of this Warrant is redeemed, on the Redemption Date (as defined below) for such portion) but not thereafter, to subscribe for and purchase from DSS, Inc., a New York corporation (the “Company”), up to 8,000,000 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book-ent

…

SECURITIES PURCHASE AGREEMENT

** **

This Securities Purchase Agreement (this “Agreement”) is dated as of September 15, 2026, between DSS, Inc., a New York corporation (the “Company”), and Alset, Inc., a Texas corporation (including its successors and assigns, the “Purchaser”).

WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act (as defined below), and Rule 506 promulgated thereunder, the Company desires to issue and sell to the Purchaser, and the Purchaser desires to purchase from the Company, securities of the Company, consisting of a convertible promissory note in the amount of $500,000 that shall be convertible, following receipt of Stockholder Approval, into shares of the Common Stock of the Company at a conversion price set at $0.50 per share, subject to the terms and conditions set forth therein (the “Note”) and warrants to purchase 8,000,000 shares of the Common Stock of the Company (which the parties hereto acknowledge is equal to eight (8) Warrant Shares for every one (1) share initiall

…

THIS PROMISSORY NOTE (“NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

PROMISSORY NOTE

	Dated as of September 18, 2026
Principal Amount: Up to $300,000	Manhattan Beach, CA

…

THIS PROMISSORY NOTE (“NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

** **

PROMISSORY NOTE

September 18, 2026

Principal Amount: $544,080

…

September 16, 2026

John Landry

10 Days Landing

Biddeford, ME 04005

Dear John,

On behalf of CVRx, Inc. (“CVRx” or the “Company”), I am pleased to offer you employment with CVRx. Subject to fulfillment of the conditions of employment mentioned in this letter, your estimated hire date will be October 12, 2026, pending successful completion of enclosed policy acknowledgements and pre-employment screening described below.

Commencing the day following the Company’s filing of its Form 10-Q for the quarter ending September 30, 2026, you will transition to the full-time role of Chief Financial Officer reporting to Kevin Hykes, Chief Executive Officer, and serving as an “executive officer” of the Company. This filing is expected to occur in early November 2026. In your capacity as Chief Financial Officer, you will serve as the Company’s principal financial officer and an officer for purposes of Section 16 of the Securities Exchange Act of 1934, and you will also serve as the Company’s principal accounting officer, treasurer and such other positions as the Company may reasonably request f

…

September 21, 2026

Eric Dube, Ph.D.

Via E-mail

Re:    Transition and Separation Agreement

Dear Eric:

This letter agreement (the “Agreement”) sets forth our mutual understanding regarding your decision to step down as President and Chief Executive Officer of Travere Therapeutics, Inc., a Delaware corporation (the “Company”).

1.Resignation. You hereby inform the Company of your intent to voluntarily resign as the Company’s President and Chief Executive Officer and as a member of the Board of Directors of the Company, and from all other officer or director roles held by you at the Company or at any subsidiary of the Company, effective as of December 1, 2026, or such earlier date as is mutually agreed upon by you and the Company (the actual date of such resignation, the “Officer Resignation Date”).

…

EMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENTis entered into by and betweenTravere Therapeutics, Inc., a Delaware corporation (hereinafter the “Company”), and Bradley Campbell (hereinafter “Executive”).

R E C I T A L S

WHEREAS, the Company and Executive wish to set forth in this Agreement the terms and conditions under which Executive will be employed by the Company on and after the Start Date.

NOW, THEREFORE, the Company and Executive, in consideration of the mutual promises set forth herein, agree as follows:

1.

NATURE OF EMPLOYMENT

1.1 Start Date of Employment.Executive’s employment with the Company shall begin on December 1, 2026 or such date as otherwise agreed to by Executive and the Company (such actual date Executive’s employment begins (the “Start Date”)).

1.2 Effect of Agreement.This Agreement shall govern the terms of Executive’s employment with the Company on and after the Start Date until it is terminated by either the Company or Executive pursuant to the terms set forth in Article 6.

…

FIRST AMENDMENT TO NOMINATION AND COOPERATION AGREEMENT

This First Amendment to Nomination and Cooperation Agreement (this “Amendment”), dated as of September 17, 2026, is entered into by and among Jack in the Box Inc., a Delaware corporation (the “Company”), and GreenWood Investors, LLC (together with the entities listed on Schedule Ato the Cooperation Agreement (as defined below), “GreenWood”). GreenWood and the Company are referred to herein as the “Parties.”

WHEREAS, the Company and GreenWood entered into that certain Nomination and Cooperation Agreement, dated November 3, 2025 (the “Cooperation Agreement”);

WHEREAS, the Parties desire to (i) extend the term of the Cooperation Agreement for an additional one-year period and (ii) make certain other amendments to the provisions of the Cooperation Agreement as set forth in this Amendment; and

WHEREAS, Section 11 of the Cooperation Agreement permits the Parties to amend the Cooperation Agreement by a written instrument executed by the Parties.

…

JOINDER TO REGISTRATION RIGHTS AGREEMENT

The undersigned is executing and delivering this Joinder (the “Joinder”) to the Registration Rights Agreement, dated as of September 14, 2026 (as amended, modified and waived from time to time, the “Registration Agreement”), among GT Biopharma, Inc., a Delaware corporation (the “Company”), and the other persons named as parties therein (including pursuant to other joinders). Capitalized terms used herein and not otherwise defined shall have the meaning set forth in the Registration Agreement.

By executing and delivering this Joinder to the Company, the undersigned hereby agrees to become a party to, to be bound by, and to comply with the provisions of, the Registration Agreement as a Holder in the same manner as if the undersigned were an original signatory to the Registration Agreement, and the undersigned will be deemed for all purposes to be a Holder thereunder and the undersigned’s Conversion Shares and Warrant Shares will be deemed for all purposes to be Registrable Securities under the Registration Agreement.

…

FIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENT

THIS FIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENT (this “Amendment”), dated as of September 18, 2026, is entered into among GT Biopharma, Inc., a Delaware corporation (the “Company”) and each Person identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed thereto in the Securities Purchase Agreement (as defined below).

RECITALS

A. The Company, Five Narrow Lane, L.P. (“Five Narrow”), Bristol Investment Fund, Ltd. (“Bristol”) and certain other purchasers (collectively, the “Initial Purchasers”) are parties to that certain Securities Purchase Agreement, dated as of September 14, 2026 (the “Securities Purchase Agreement”).

…